C

Can-Fite BioPharma Ltd

D
CANF
USD
-0.08
(-3.7209%)
Market Closed
1,614.00
حجم التداول
-0.711
الربح لكل سهم
-
العائد الربحي
-0.796571
P/E
12,619,605.96
حجم السوق
اليوم
-3.7209%
1 اسبوع
-5.479%
1 شهر
3.500%
6 اشهر
0.000%
12 اشهر
-3.721%
بداية السنة
-2.358%
كل الوقت
0%

Title:
Can/Fite BioPharma Ltd

Sector:
Healthcare
Industry:
Biotechnology
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed intoa Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
هل تحتاج مساعدة او لديك استفسار؟